| Ma (2018) | 1) 30 (17/13)2) 30 (14/16) | 1)27.50±19.10(month)2)24.30±20.50(month) | 1)53.60±21.102)49.20±25.30 | YGCG+ Betahistine Mesilate 12mg 1T bid, Methylprednisolone 48mg qd(5 days) | Betahistine Mesilate 12mg 1T bid, Methylprednisolone 48mg qd(5 days) | 14days | ① effective rate | ① (I) 93.9% (C) 66.7% (P<0.05) | NR |
| Na (2022) | 1) 40 (24/16)2) 40 (23/17) | NR | NR | YGCG’+ Betahistine Mesilate 6mg 1T bid | Betahistine Mesilate 6mg 1T bid | 1month | ① effective rate② TCM③ blood rheological indexes④ SF-36 | ① (I) 95.00% (C) 77.50% (P<0.05)② dizziness (I) 4.56±0.73 (C) 3.18±0.45 (P<0.05)tinnitus (I) 0.73±0.11 (C)1.36±0.28 (P<0.05)hearing (I) 3.28±0.64 (C)2.17±0.42 (P<0.05)③ plasma viscosity/mpa•s (I) 1.69±0.22 (C)1.93±0.23 (P<0.05)fibrinogen/(g/L) (I) 1.93±0.23 (C) 1.93±0.23 (P<0.05)hematocrit/L (I) 1.93±0.23 (C) 1.93±0.23 (P<0.05)④ physical function (I) 82.63±3.14 (C) 70.39±5.24 (P<0.05)mental health (I) 84.59±3.24 (C) 72.34±4.28 (P<0.05)social function (I) 83.97±3.22 (C) 73.29±4.72 (P<0.05)emotional function (I) 85.26±3.28 (C) 74.36±5.22 (P<0.05) | NR |
| Wang (2022) | 1) 40 (16/24)2) 40 (23/17) | 1)3.1±1.1(year)2)3.4±1.3(year) | 1)50.5±7.12)51.8±7.9 | YGCG’+ Betahistine Mesilate 6mg 1T bid | Betahistine Mesilate 6mg 1T bid | 30days | ① effective rate② DHI③ TCM④ Immunoglobulins and complement⑤ T lymphocytes | ① (I) 95.00% (C) 77.50% (P<0.05)② (I) 19.5±4.7 (C) 28.1±8.5 (P<0.05)③ tinnitus (I) 2.1±0.4 (C) 3.3±0.7 (P<0.05)hearing (I) 1.9±0.6 (C) 3.0±0.4 (P<0.05)④ IgG (I) 9.93±2.79 (C) 11.63±2.54 (P<0.05)IgA (I) 1.81±0.35 (C) 2.09±0.51 (P<0.05)IgM (I) 1.32±0.57 (C) 1.41±0.47 (P=0.443)C3 (I) 1098.4±301.2 (C) 1275.9±314.7 (P<0.05)C4 (I) 471.5±165.8 (C) 503.4±170.8 (P=0.399)⑤ CD3 (I) 69.35±5.35 (C) 63.75±6.11 (P<0.05)CD4 (I) 46.39±5.72 (C) 43.12±6.85 (P<0.05)CD8 (I) 27.15±7.19 (C) 31.37±6.86 (P<0.05) | (I) 5.00% (C) 7.50% (P=0.465) |
| Chen (2021) | 1) 40 (24/16)2) 40 (23/17) | 1)1.25±0.14(year)2)1.24±0.13(year) | 1)53.94±3.182)53.89±3.16 | YGCG’+ Betahistine Mesilate 6mg 1T bid | Betahistine Mesilate 6mg 1T bid | 30days | ① TCM② SF-36 | ① dizziness (I) 4.56±0.73 (C) 3.18±0.45 (P<0.05)tinnitus (I) 0.73±0.11 (C)1.36±0.28 (P<0.05)hearing (I) 3.28±0.64 (C)2.17±0.42 (P<0.05)② physical function (I) 82.63±3.14 (C) 70.39±5.24 (P<0.05)mental health (I) 84.59±3.24 (C) 72.34±4.28 (P<0.05)social function (I) 83.97±3.22 (C) 73.29±4.72 (P<0.05)emotional function (I) 85.26±3.28 (C) 74.36±5.22 (P<0.05) | NR |
| Liu (2018) | 1) 34 (NR/NR)2) 34 (NR/NR) | NR | 1)61.68±10.982)61.21±11.41 | YGCG+ 参芎 inj. 20mL + 5% dextrose inj. 250mL, 奥拉西坦 inj. 15mL+ 5% N/S 100mL qd IV inj. | 参芎 inj. 20mL + 5% dextrose inj. 250mL, 奥拉西坦 inj. 15mL+ 5% N/S 100mL qd IV inj. | 14days | ① DHI② Pure tone audiometry | ① (I) 29.47±9.06 (C) 36.94±9.47 (P<0.05)② (I) 70.59% (C) 50.00% (P<0.05) | NR |
| Wang (2013) | 1) 47 (20/27)2) 46 (21/25) | 1) 1-15year | 1)18-252)19-65 | YGCG‘ | WM | 7 days | ① effective rate | ① (I) 95.7% (C) 84.8% (P<0.05) | NR |
| Han (2014) | 1) 42 (2/40)2) 39 (18/21) | 1) 2months-5years2) 2months-5years | 1)32-65year2)23-65year | YGCG+WM | WM | 7 days | ① effective rate | ① (I) 95.2% (C) 84.6% (P<0.01) | NR |